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The ability of lentiviruses to infect terminally differentiated/
nondividing macrophages is unique among retroviruses (Lewis
et al., 1992; Lewis and Emerman, 1994; Weinberg et al., 1991) and
also important for their utility as gene delivery tools for nondividing
cell types such as neurons (Naldini et al., 1996). The infection of
macrophages by human immunodeﬁciency virus type 1 (HIV-1)
produces a landmark viral phenotype in the early phase of HIV-1
pathogenesis (Crowe et al., 2003; Verani et al., 2005). Various viral
elements have been identiﬁed that enable lentiviruses to infect
nondividing cells, such as Vpr, the central polypurine tract (cPPT)-
DNA ﬂap, and reverse transcriptase (RT) (as reviewed by Yamashita
and Emerman) (De Rijck et al., 2007; Yamashita and Emerman, 2006).
We have also previously reported that lentiviral RTs are able to aid in
the infection of non-diving cells by efﬁciently synthesizing proviral
DNA in limited dNTP pools, such as those found inmacrophage, due to
their unique high afﬁnity to dNTP substrates (Diamond et al., 2004).
The cPPT sequence, which is found among lentiviruses (Charneau
et al., 1992), lies at the exact center of the ~9.6 kb long HIV-1 RNA
genomewithin the coding regionof the integrasegene. A key functionof
the cPPT is to generate an additional RNA primer to initiate second (+)
strand viral DNA synthesis (Charneau et al., 1992). The cPPT-central
termination sequence (CTS) has also been proposed to create a ﬂap atthe end of (+) strand DNA synthesis, which is recognized by unknown
host/viral factors (Arhel et al., 2007). Thisﬂap is believed to enhance the
nuclear import of the pre-integration complex (PIC) in nondividing cells
(Zennou et al., 2000). However, since the ﬂap does not have to be
generated at the exact middle in order to be recognized by host or viral
factors (De Rijck et al., 2005), the reason why the cPPT lies at the center
of the genome still remains unclear. Furthermore, the role of the cPPT in
nuclear import also remains controversial, since it has been shown that
HIV-1 lacking the cPPT still efﬁciently replicates in macrophages and
CD4+ T cells (Dvorin et al., 2002; Marsden and Zack, 2007).
We have recently reported that the addition of the cPPT can
compensate for the delayed proviral DNA synthesis in a 3-vector
system under the control of a cytomegalovirus promoter. The HIV-1
vectors harbored the RT mutants, V148I and Q151N, which are
defective in binding to dNTPs and thus fail to synthesize proviral DNA
in cells with low dNTP concentrations, such as macrophages (Skasko
and Kim, 2008). This ﬁnding suggested that the cPPT is necessary for
HIV-1 to accelerate (+) strand DNA synthesis by creating an
additional priming site, which can shorten the length of (+) strand
synthesis replicated by one primer from 9.6 kb to ~5 kb. Thus, it
would be reasonable to assume that the cPPT becomes more critical
for HIV-1 replication in macrophages where the viral replication
kinetics are slow due to limited dNTP pools (Diamond et al., 2004),
and during the delayed replication of HIV-1 vector containing partially
defective RT mutations such as Q151N and V148I (Diamond et al.,
2004; Jamburuthugoda et al., 2006, 2008).
The HIV-1 M184I RT mutation is clinically important due to its 3TC
resistance, which can be generated through the deamination of
cytosine at this residue by APOBEC3G (Mulder et al., 2008). This RT
Fig. 1. Effect of cPPT mutation and cellular dNTP level on transduction efﬁciency of HIV-1
vector. (A) Nucleotide sequences of wild type and mutant NL4-3 cPPTs used in this study.
The translated amino acid sequenceof the cPPT is a part ofHIV-1 integrase. (B) Effect of the
cPPT mutation on the transduction of the WT RT vector in dividing (serum) and
nondividing primary human lung ﬁbroblasts (HLFs) with (serum-starved with 1 mM dN)
and without (serum-starved) the elevation of cellular dNTP levels. Primary HLFs were
plated, 2.5×105, inmedia containing 10% serum and then inmedia containing 0.2% serum
for 48 h in the presence and absence of 1 mM dNs. HLFs cultured under these conditions
were transduced with 2.77×105 pg of WT RT HIV-1 vector with (+) or without (−) the
cPPT. The transduced cells were analyzed by FACS for GFP expression at 48 h post
transduction and the transduction efﬁciency was plotted. The experiments presented in
this ﬁgure were performed at least in triplicate.
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in a M184V mutation (Frost et al., 2000). The transient nature of the
M184I mutation is likely due to its limited replicational ﬁtness,
compared to the M184V mutation (Domaoal et al., 2008; Frost et al.,
2000). In fact several biochemical defects in the M184I mutant RT
have been reported (Gao et al., 2008; Jamburuthugoda et al., 2008;
Saraﬁanos et al., 1999). The β-branched side chain of isoleucine in
M184I reduces the binding afﬁnity of RT for dNTP substrates and
raises its Kd approximately 50-fold (from 1 μM of WT RT Kd to 56 μM)
(Jamburuthugoda et al., 2008). Thus M184I RT exhibits a severely
decreased activity at low dNTP concentrations (Jamburuthugoda
et al., 2008), whereas M184V RT, which displays WT levels of dNTP
binding afﬁnity (Domaoal et al., 2008), remains enzymatically active
at both the low and high dNTP concentrations found in macrophages
and activated CD4+ T cells, respectively (Aquaro et al., 2005;
Diamond et al., 2004). Structural studies also demonstrated that the
M184I mutation alters the template–primer interactions of RT, which
explains its reduced processivity (Gao et al., 2008).
In this report, we investigated the mechanistic interplay between
host dNTP pools, HIV-1 RT dNTP binding afﬁnity and cPPT with
respect to viral sensitivity and resistance to RT inhibitors. We have
identiﬁed a speciﬁc compensatory relationship between the viral
resistance of M184I HIV-1 RT and its dependence on the cPPT and
cellular dNTP concentrations.
Results
The effect of the cPPT and cellular dNTP concentrations on HIV-1
replication
First, we investigated the effects of the cPPT mutation and the
cellular dNTP concentrations on the transduction efﬁciency of a HIV-1
vector in primary human lung ﬁbroblasts (HLF). HLFs have been used
as an ideal model system for both dividing and nondividing cells
because their cell cycles can be easily manipulated (Jamburuthugoda
et al., 2008; Skasko and Kim, 2008). In addition, the cellular dNTP
concentrations of HLFs can be modulated by both deoxynucleoside
(dN) treatment and serum starvation (Jamburuthugoda et al., 2006).
Dividing HLFs cultured in 10% serum have an intracellular dNTP
concentration of approximately 150−300 nM (Jamburuthugoda et al.,
2006), which is higher than the dNTP concentration found in human
macrophages (~50 nM), but lower than activated CD4+ T cells
(2−4 μM) (Charneau et al., 1992; Diamond et al., 2004). Treating
dividing and nondividing HLFs with deoxynucleosides (dNs) elevates
their cellular dNTP concentration to 50 μM and ~1 μM, respectively
(Jamburuthugoda et al., 2008). In this study, we employed a VSV-G
pseudotyped D3HIV-GFP vector which encodes a ~9.6 kb long HIV-1
NL4-3 based RNA genome similar to the length of an infectious HIV
genome, and expresses all HIV-1 proteins except for Env and Nef,
which was replaced with GFP. The cPPT sequence of this vector was
inactivated by mutating a series of purine bases to pyrimidine bases
without altering the amino acid sequence of the integrase gene
(Fig. 1A), as described previously (Charneau et al., 1992).
First, we transduced HLFs with an equivalent p24 level
(2.77×105 pg) of the (+) and (−) cPPT WT RT HIV-1 vectors
and cultured them in three separate media conditions; 10% serum
that allows for cellular division, 0.2% serum (nondividing), and also
0.2% serum supplemented with 1 mM of dNs. GFP expression was
determined through FACS analysis at 48 h post transduction. As
shown in Fig. 1B, the cPPT mutation had only a 1.8-fold decrease in
the WT RT vector transduction in dividing HLFs, while a 7.7-fold
decrease was observed by the cPPT inactivation in nondividing
HLFs. Combining cPPT inactivation and nondividing culture condi-
tions led to a 9-fold decrease of the WT RT vector transduction. This
large decrease in transduction with nondividing HLFs could be due
to loss of the cPPT functions in both nuclear import and thereplication enhancement during (+) strand DNA synthesis. How-
ever, as seen in Fig. 1B, the treatment with dNs only slightly (1.5×)
compensated for the 9-fold transduction decrease seen in the
nondividing HLFs. This minimal compensation by the dN treatment
supports the idea that a major factor for the cPPT inactivation,
which induced a 9-fold decrease of the WT RT vector transduction
in nondividing cells, is the loss of the nuclear import function of
cPPT which cannot be compensated by the elevation of cellular
dNTP concentrations. In addition, the minimal effect of the dN
treatment is predictable because WT RT alone is sufﬁcient for the
efﬁcient proviral DNA synthesis even at very low concentrations
found in nondividing cells without the dNTP level elevation.
Roles of the cPPT and cellular dNTP pools in a HIV-1 vector harboring the
3TC resistant M184I RT mutant
Next, we investigated the effects of the cPPT mutation and cellular
dNTP concentrations on the transduction of the HIV-1 vector bearing
the M184I RT variant. M184I RT displays reduced polymerase activity
and is clinically relevant due to its 3TC resistance (Jamburuthugoda
et al., 2008; Li et al., 2009). This mutant appears transiently but
consistently during 3TC treatment and ultimately results in M184V
(Frost et al., 2000). Importantly, we have previously reported that the
M184I RT displays a signiﬁcantly reduced dNTP binding afﬁnity when
compared to the wild type (WT) RT. However, the reduced activity of
Fig. 2. Effect of cPPTmutation on the transduction efﬁciency and proviral DNA synthesis
of HIV-1 vector harboring M184I mutant RTs. (A) Transduction efﬁciency of (+) and
(−) cPPT M184I vectors in HLFs cultured in 10% serum, 0.2% serum and 0.2% serum
with 1 mM dNs. HLFs were transduced with an equal p24 level, 2.77×105 pg of (+) and
(−) cPPT M184I RT HIV-1 vectors, and the transduction efﬁciency was determined as
described in Fig. 1B. (B) Quantitative 2LTR circle PCR assay of the (+) and (−) cPPT
M184I vector in the serum-starved HLFs. Genomic DNA of serum-starved HLFs
transduced with the M184I virus was prepared at 48 h post transduction and used for
the quantitative 2LTR PCR to monitor the kinetics of the proviral DNA synthesis and
normalized with genomic cellular DNA as previously described (Jamburuthugoda et al.,
2006; Skasko, and Kim, 2008). (C) The LTR/gag late reverse transcription product
synthesized from the 3′LTR was measured for the (+) and (−) M184I vector in the
serum-starved HLF at 48 h post transduction as described in Materials and procedures.
The treatment with 2 μM Nevirapine and 1 μM AZT, which block viral reverse
transcription, was employed for assessing the PCR background control. The experi-
ments presented in this ﬁgure were performed at least in triplicate.
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(Jamburuthugoda et al., 2008).
First, we characterized the transduction of the M184I HIV-1 with
respect to cell division, cellular dNTP concentration and inactivation
of the cPPT primer. HLFswere cultured inmedia with 1) 10% serum, 2)
0.2% serum, and 3) 0.2% serumwith 1 mM dNs. They were transduced
with M184I (+) and (−) cPPT vectors with the same p24 level
(2.77×105 pg) used for theWT RT vectors in Fig. 1B. The transduction
efﬁciencies of each vector were determined by FACS analysis for GFP
expression at 48 h post transduction. As shown in Fig. 2A, the M184I
mutant vector showed ~70% transduction efﬁciency in dividing HLFs,
which is only slightly reduced when compared to WT (~80%, Fig. 1B).
The cPPT mutation in the M184I vector induced a 2.6-fold transduc-
tion decrease in dividing cells, and this reduction is also very similar to
the reduction observed with the WT vector (Fig. 1B). In nondividing
HLFs, the transduction of the M184I vector decreased 7.3-fold (to 8%),
compared to the dividing cells (Fig. 2A), and this is contrasted to the
WT RT vector which displayed a similar transduction efﬁciency in
both dividing (~80%) and nondividing HLFs (~70%) (Fig. 1B). In
nondividing cells, the cPPT mutation in the M184I vector caused a
3-fold further decrease in transduction (Fig. 2A), while the WT RT
vector showed a 7.7-fold decrease (Fig. 1B). Basically, the M184I
(−) cPPT vector almost failed to transduce nondividing HLFs (b2%),
supporting that the cPPT inactivation and M184I RT mutation
additively reduced the vector transduction in nondividing HLFs.
However, when the cellular dNTP pools were elevated by the dN
treatment (Fig. 2A), both (+) and (−) cPPT M184I vector
signiﬁcantly gained transduction efﬁciency, supporting that the
dNTP concentration increase can at least partially compensate for
both the M184I and cPPT mutations. Therefore, it is apparent that
the elevation of the cellular dNTP level could signiﬁcantly
compensate for the replicational delay induced by the M184I
mutation and low dNTP concentration of the nondividing cells,
leading to a larger increase (6.6×) of the M184I vector transduction
efﬁciency in the nondividing cells treated with dNs, compared to
the WT RT vector (1.5×, Fig. 1B).
Next, we investigated if the cPPT inactivation, which further
reduced the transduction efﬁciency of the M184I vector in nondivid-
ing HLFs, directly impacted proviral DNA synthesis kinetics. For this,
we conducted a 2LTR Q-PCR assay; 2LTR circles are a result of the end
joining of proviral DNA in the nucleus post completion of reverse
transcription and nuclear import, and have been used for a marker for
completed proviral DNA synthesis and nuclear import (Butler et al.,
2002; Van Maele et al., 2003). We also simultaneously examined the
copy number of LTR–gag late product which is replicated from the 3′
PPT (Sun et al., 1997). As shown in Figs. 2B and C, a drastic decrease in
the 2LTR copy number in the M184I (−) cPPT vector was observed,
compared to the M184I (+) cPPT vector in nondividing HLFs, while
the copy number of the late product synthesized from the 3′ PPT was
not affected by the cPPT deletion. Thus, the reduction of the 2LTR
circle copy numberwas likely due to the deletion of the additional PPT
primer and ﬂap, which affects the (+) strand synthesis kinetics and
nuclear import, respectively.
Rescue of the M184I (−) cPPT mutation by WT RT molecules
Next, we tested if the reduced transduction of the M184I RT (−)
cPPT vector in nondividing HLFs could be rescued by introducing WT
RTmolecules into the virion of the M184I vector. It was predicted that
co-packaging of the WT HIV-1 RT together with the M184I RT within
the same capsid could rescue the biochemical defects induced by the
M184I RT mutation. We prepared hybrid HIV-1 vectors, which have
been previously described (Julias et al., 2001), harboring bothWT and
M184I RT molecules in different ratios within the same virion. Brieﬂy,
these hybrid vectors were prepared by transfecting 293FT cells with
varying ratios of WT to M184I RT packaging plasmids, and used to
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two RT constructs are equally efﬁcient as demonstrated by the almost
equal p24 levels of the vector particles produced from the different
mixtures of the two RT plasmids (data not shown). The transduction
efﬁciency of each vector was determined through FACS analysis and
ﬂuorescence microscopy as presented in Figs. 3A and B. Indeed, the
M184I vectors with higher ratios of co-packaged WT RT protein,
exhibited an increased number of GFP-expressing cells (Fig. 3A), and
thus a higher transduction efﬁciency (Fig. 3B). These data conﬁrm that
the cause of the decreased transduction efﬁciency of the M184I vector
in nondividing cells was due to delayed reverse transcription resulting
from the decreased polymerase kinetic activity of M184I RT, especially
at low cellular dNTP pools found in nondividing cells.
Effect of the cPPT mutation on the sensitivity of HIV-1 M184I vector to
3TC and other RT inhibitors
Next, we tested if the replication delay induced by the cPPT
mutation could affect the sensitivity of the HIV-1 vector to RT
inhibitors, which directly interrupts proviral synthesis. To test this we
investigated the effect of the cPPT mutation on the sensitivity of the
M184I vector to 3TC. M184I RT has been previously shown to have a
high resistance to 3TC due to the steric hindrance between the
isoleucine of RT and 3TC (Saraﬁanos et al., 1999). Dividing HLFs were
pre-treated with varying concentrations of 3TC, and these cells were
transduced with an equal p24 level of the (+) and (−) cPPT M184I
vectors. As shown in Fig. 4A, HLFs treated with 500 μM 3TC, which is
~300 times higher than the previously published IC50 values of theWT
RT HIV-1 (Yoshimura et al., 1999), still maintained efﬁcient
transduction levels with the M184I (+) cPPT vector, conﬁrming the
high 3TC resistance of the M184I RT. In contrast, a large transduction
decreasewas clearly observed at 500 μMof 3TC in theM184I (−) cPPTFig. 3. Compensation of the transduction defect of the M184I (−) cPPT HIV-1 vector by
percentages of WT RT to M184I RT in a single viral particle (100% M184I, 90% M184I to 10%W
starved HLFs were transduced with an equal p24 amount of the constructed hybrid vector
transduction, and the overlaid pictures were constructed. At the same time, the transduct
experiments presented in this ﬁgure were performed at least in triplicate.vector, suggesting that the cPPT inactivation counteracts the strong
3TC resistance of the M184I RT mutation. Next, we examined the 3TC
dose dependence of the M184I RT (+) and (−) cPPT vectors. As seen
in Fig. 4B, the M184I (+) cPPT vector exhibited a high resistance to
3TC, and only a minimal decrease in transduction was seen with this
vector even at 750 μM 3TC. In contrast, the M184I (−) cPPT vector
displayed a signiﬁcant decrease in its resistance to 3TC. Since the
M184I (+) cPPT vector displays a high 3TC resistance, we were only
able to determine the IC25 value, the drug concentration yielding 25%
inhibition (Fig. 4B). Indeed, we found that cPPT inactivation causes a
30-fold increase in viral sensitivity to 3TC.
Next, we tested if the same drug sensitization in the M184I (−)
cPPT vector could be observed with AZT or Nevirapine. Dividing HLFs
were pre-treated with various concentrations of AZT (Fig. 4C) or
Nevirapine (NEV, Fig. 4D), and were transduced with the M184I (+)
and (−) cPPT vectors. The IC50 values with each drug treatment were
determined and summarized in Table 1. Indeed, both the M184I (+)
and (−) cPPT vectors showed very similar IC50 values for AZT and
NEV. This suggests that the sensitivity of the M184I (−) cPPT vector is
exclusive to 3TC.
Effect of speciﬁc cellular dNTP pool changes on the 3TC sensitization
property of the M184I (−) cPPT vector
Next, we investigated possiblemechanistic explanations of the 3TC
sensitization effect of the cPPT inactivation in M184I vector. First, we
measured the 3TC sensitivity of the M184I (+) and (−) vectors in the
HLFs with elevated pools of all four dNTPs. As shown in Fig. 5A, both
M184I (+) and (−) cPPT vectors displayed strong 3TC resistance, and
thus the 3TC sensitization activity of the cPPT mutation could be
effectively eliminated by the 1 mM dN treatment (Fig. 5A). Next, we
tested if the loss of the 3TC sensitization effect is nucleotide-speciﬁcthe incorporation of WT HIV-1 RT. (A) (−) cPPT HIV-1 vectors containing different
T, 50% M184I to 50%WT, 10% M184I to 90%WT, 100%WT) were prepared. The serum-
s. The pictures of the transduced cells in bright ﬁeld and GFP were taken at 48 h post
ion efﬁciency was determined by FACS analysis for the GFP-expressing cells (B). The
Fig. 4. Effect of the cPPT mutation on 3TC sensitivity of HIV-1 M184I vector. (A) The transduction efﬁciency of the M184I (+) and (−) cPPT HIV-1 vectors in dividing HLFs in the
presence of 500 μM 3TC. (B) 3TC dose dependence of the M184I (+) and (−) cPPT vectors. (C) AZT dose dependence of the M184I (+) and (−) cPPT vectors. (D) Nevirapine dose
dependence on the M184I (+) and (−) cPPT vectors. HLFs were transduced with an equal p24 level of the (+) and (−) cPPT vectors in dividing HLFs pre-treated with varying
concentrations of 3TC, AZT or Nevirapine. The transduction efﬁciencies at each of the concentrations in (B), (C) and (D) were normalized with that of the drug free control (100%).
The IC25 and IC50 values were marked with a dotted line. The experiments presented in this ﬁgure were performed at least in triplicates.
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other three dNs. For this test, we treated HLFs with 1 mMdC alone or a
mixture of dG, dT and dA, and measured the 3TC sensitivity of the
M184I (−) cPPT vector. As shown in Fig. 5B, upon dC treatment, the
M184I (−) cPPT vector gained a strong resistance to 3TC. In contrast,
when increasing the remaining other three dNTPs, the M184I (−)
cPPT vector remained sensitive to 3TC, demonstrating that a high
concentration of only cellular dCTP abolishes the 3TC sensitivity of the
M184I vector gained by the cPPT inactivation.
Finally, we examined if theWT (−) cPPT vector would also display
an increased sensitivity to 3TC, AZT or NEV treatment. As shown in
Table 1, the cPPT mutation did not increase the sensitivity of WT RT to
3TC. In addition, the IC50 values of AZT and NEV for the WT (+) and
(−) cPPT vectors remained the same. These data demonstrate that the
drug sensitization effect of cPPT inactivation is exclusive to 3TC and
the M184I (−) cPPT vector.Table 1
IC50 values of WT and M184I (+) and (−) cPPT HIV-1 vectors to 3TC, AZT and NEV in
dividing HLFs.
IC50 values
3TC AZT NEV
WT RT vectors
(+) cPPT 2.4 μM±4.98 0.8 μM±12.63 169 nM±4.26
(−) cPPT 2.4 μM±2.88 0.8 μM±9.463 93 nM±4.628
M184I RT vectors
(+) cPPT N750 μM±2.09 0.8 μM±12.03 166 nM±4.13
(−) cPPT 10 μM±6.821 0.9 μM±7.16 93 nM±5.875Discussion
Proviral DNA synthesis of retroviruses is a very complex process
requiring both host and viral factors for its efﬁcient completion,
particularly in nondividing cells (Yamashita and Emerman, 2006). In
this study we further characterized these elements, identiﬁed interac-
tive relationships between them, and assessed their contributions to
viral RT inhibitor sensitivity. Predictably, elements that can affect the
DNA polymerization rate of RT, such as dNTP concentration and the
binding afﬁnity of RT to dNTPs,were able to alter proviral DNA synthesis
kinetics. We have previously reported that the RTs of lentiviruses
uniquely synthesize DNA efﬁciently at the low dNTP concentrations
found in nondividing cells, such as macrophages (Diamond et al., 2004;
Jamburuthugoda et al., 2008). This is a unique biochemical feature and
can be contrasted to the RTs of oncoretroviruses that fail to synthesize
DNA efﬁciently at low dNTP concentrations and infect only dividing
cells. These observations suggested that HIV-1 and other lentiviral RTs,
may have evolved a unique ability to utilize substrates that fall within a
broad concentration range varying between its two main target cell
types, macrophage and activated CD4+ T cells.
We have also recently identiﬁed the cPPT as a viral element that
contributes toward efﬁcient proviral DNA synthesis of HIV-1, by
dually initiating the (+) strand synthesis and thus shortening the
genome distance per primer required to compete the (+) strand HIV-
1 DNA synthesis (Skasko and Kim, 2008). This efﬁcient proviral DNA
synthesis was found to be particularly important in cell types bearing
low dNTP concentrations. We were also able to demonstrate that the
cPPT could compensate for the delayed proviral DNA synthesis
induced by dNTP defective binding RT mutants such as Q151N and
V184I (Skasko and Kim, 2008).
Here we investigate the cPPT and the cellular dNTP concentrations
with respect to the transduction of the M1841 vector and its sensitivity
Fig. 5. Effect of dN treatment on M184I (−) HIV-1 vector sensitivity to 3TC. (A) 3TC
dose dependence of the M184I (+) and (−) cPPT vectors in HLFs pre-treated with
1 mM dN. (B) The transduction of the M184I (−) cPPT vectors in dividing HLFs in the
presence and absence of 1 mM dC or a mixture of 1 mM dA, dT, and dG. HLFs were
transduced with an equal p24 level of the (−) cPPT M184I RT vectors in dividing HLFs
pre-treated with varying concentrations of 3TC. The transduction efﬁciency at each of
the concentrations was normalized with that of the drug free control (100%). The
experiments presented in this ﬁgure were performed at least in triplicate.
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RT mutation additively reduce the vector transduction efﬁciency and
proviral DNA synthesis kinetics. This reduced transduction could
become further pronounced by eliminating cellular division, which
both lowers cellular dNTP concentration and requires the nuclear
import function of cPPT. This reduction is partially rescued by elevating
both cellular dNTP concentrations and viral DNA polymerization
capacity by incorporating WT RT molecules into the M184I vector. It
can be presumed that by increasing intracellular dNTP pools, theM184I
vector is rescued from its dNTP binding defect. However, this rescue
seen with dN treatment is unique to dividing cells. This is likely due to
the additional requirement for the nuclear import function of the cPPT
ﬂap in nondividing cells, which cannot be compensated by an increased
rate of proviral DNA synthesis.
Importantly, the M184I mutant vector lost its 3TC resistance upon
the cPPT inactivation. Since this effectwasobserved individingcells, this
sensitization could not be due to the loss of the nuclear import function
of the cPPT. However, this drug sensitization effect seenwith theM184I
(−) cPPT vector was observed only with 3TC, not AZT or NEV. In
addition, theWT(−) cPPTvectordidnotdisplayan increased sensitivity
to any of the drugs used in this study. Therefore, we believe the
sensitivity to 3TC observed is exclusive to the M184I (−) cPPT vector.
One possible cause for this speciﬁcity could be the use of high
concentrations of 3TC during the drug titration curves of the M184I
vector. These high concentrations of 3TCmay result in a decrease in the
cellular concentrations of dCTP and/or all dNTPs, by forcing amajority of
cellular nucleoside phosphorylation machinery to 3TC. The resultinglimiteddNTPpoolwould not affect theproviral DNA synthesis ofWTRT.
WT RT is able to synthesize proviral DNA efﬁciently even at very low
dNTP concentrations due to its high binding afﬁnity to dNTPs, but the
limited dNTP pools induced by the treatment with high 3TC concentra-
tionswould affect theM184I RTdue to its reduceddNTPbindingafﬁnity.
We tested this possibility by increasing the cellular dC concentrations
after HLFs were treated with 3TC. Indeed, we observed that only the
elevation of dCTP, not the other three NTPs, abolished the sensitivity of
theM184I (−) cPPT vector to 3TC. Thus this data supports the idea that,
the cellular dCTP limitation induced by the high concentration of 3TC
may be a cause of the replication restriction of theM184I vector, instead
of the direct inhibition through 3TC incorporation, especially when the
replication kinetic role of cPPT is inactivated by the cPPT mutation.
Importantly, it is possible that the pre-treatment with dC may also
reduce the phosphorylation of 3TC to 3TCTP which is an active drug
form of 3TC. But this possibility was excluded because the limitation of
the 3TCTP synthesis should result in the increase of the 3TC resistance,
and instead we observed the decrease of the 3TC resistance.
One would expect that the M184I (−) cPPT vector would become
more sensitive to AZT because, like 3TC, AZT is a nucleoside analog that
also requires phosphorylation by cellular machinery (Sommadossi,
1998). However, the cPPT inactivation did not affect the sensitivity of
the M184I (−) cPPT vector to AZT. Importantly, unlike 3TC, the low
concentrationsofAZT in this study (b6 μM)were sufﬁcient to inhibit the
replication of theM184I vector because theM184I RT is still sensitive to
3TCTP like WT RT, and the treatment with the low AZT concentration
should not affect the cellular dNTP (dTTP) pools (Sommadossi, 1998).
Indeed, it has been previously shown that 5 μMof AZT only inhibits 50%
of thymidine phosphorylation (Sommadossi, 1998; Susan-Resiga et al.,
2007). Interestingly, a slight decrease of theNEV sensitivitywas induced
by the cPPT inactivation in theM184I vector.While it is possible that the
delayed replication by the cPPT inactivation may be further delayed by
the reduction of the enzymatically capable free M184I RTs induced by
NEV binding, this effect appears to be minimal.
Finally, we also observed that theWT (−) cPPT did not display any
sensitivity to the drugs used in this study. There could be two possible
explanations for this. First, the low concentrations of AZT and 3TC
used in the drug titration curves withWT vector were not sufﬁcient to
affect the dNTP synthesis machinery. Second, unlike M184I RT, WT
HIV-1 RT is highly functional even at low dNTP concentrations.
Therefore, if the dNTP pool were to decrease, it would have little effect
on the polymerization capability of WT RT due to its high binding
afﬁnity for dNTPs.
In this study, we did not conduct experiments with the M184V RT
vector, because, unlike M184I RT, the pre-steady state kinetic analysis
demonstrated that M184V RT has a WT RT level of dNTP binding
afﬁnity (Domaoal et al., 2008). This biochemical data also explains
why the M184I RT further mutates to M184V during the 3TC
treatment. Therefore, considering M184V RT in terms of its dNTP
binding afﬁnity, we postulate that cPPT removal should not
signiﬁcantly affect the 3TC resistance of the M184V vector even
though the treatment with high concentrations of 3TC may restrict
the cellular dNTP pools.
Here we present a comprehensive study that inter-connects various
host and viral factors that HIV-1 employs to achieve efﬁcient proviral
DNA synthesis. By altering these factors such as RT activity and cellular
dNTP concentrations, wewere able to detect the speciﬁc interplay of the
cPPT sequence with 3TC resistance of the M184I HIV-1 vector.
Materials and procedures
Cells and pseudotyped vector production
MRC5 primary human fetal lung ﬁbroblasts were a kind gift from
Dr. Toru Takimoto (University of Rochester). The D3HIV-GFP virus
expresses eGFP and all the HIV-1 proteins except for Nef and Env. The
259S.K. Van Cor-Hosmer et al. / Virology 406 (2010) 253–260virus was pseudotyped with vesicular stomatitis virus glycoprotein
(VSV-G) as described prior to this work (Jamburuthugoda et al.,
2008). The central polypurine tract was mutated in the pD3HIV-GFP
plasmid by PCR-based site-directed mutagenesis, through the use of a
quick-change kit (Stratagene). PCR was performed using the following
primers to mutate the cPPT: F primer — 5′-GTATTCATCCACAAATTT-
TAAAGCGCAAACCCTCCTATTGGGGGGTACAGTC-3′; R primer — 5′-
CACTGTACCCCCCAATACCACCTTTGCGCTTAAAATTGTGGATGAATAC-3′.
The M184I mutation was generated in a similar fashion as previously
described (Diamond et al., 2004). 293FTs were transfected using 1 mg/
ml of polyethylene imine (Polysciences)with 25 μg ofHIV-1 vector DNA
and 5 μg of VSV-G vector DNA. The 293FTs were washed 24 h post
transfection and supernatant was collected at 48 and 72 h after
transfection. The collected supernatant was spun in an ultra centrifuge
(Beckman) with a SW-28 rotor at 22 k for 2 h. The virus-containing
pellets from each spin were collected, treatedwith DNase, and stored at
−80 °C. The resulting pseudotyped vectors were normalized by p24
levels, which were determined through an enzyme-linked immuno-
sorbent assay system (PerkinElmer).
Cell transduction
HLFs were treated with 10 μg/ml of Polybrene (Sigma) prior to
transduction with vector that was normalized to equal p24 levels
(2.77×105 pg). HLFs were washed with DPBS 24 h after transduction.
48 h post transduction, cells were washed again with DPBS and
visualized by ﬂuorescence microscopy (Zeiss). The 48 hour time-point
was chosen because it is sufﬁcient for the completion of reverse
transcription ofWTRT vector. Also it is unlikely that the delayed reverse
transcription of the M184I mutant might eventually catch up to a WT
level of the reverse transcription at later time points, because the pre-
integration complex (PIC) of HIV has a half-life of 1 day (Pierson et al.,
2002). Following imaging, HLFswere trypsinized andmonitored for GFP
expressionbyﬂuorescent activated cell sortingusing the FL-1 channel of
a FACS Caliber (Becton Dickinson). The percent transduction was
determined using FlowJo software (version 8.8.5, Tree Star, Inc.).
2LTR circle and late product Q-PCR
HLFs were serum-starved for 2 days before transduction with the
WT (+) or (−) cPPT vectors 48 h after the transduction, genomic
extracts were prepared using SV genomic extraction kits (Promega).
The genomic extracts were then assayed for 2LTR circles or LTR–Gag
DNA by real time PCR using the following primers for the LTR regions
of 2LTR circles: 5′LTR region — 5′-GTGCCCGTCTG TTGTGTGACT-3′
and 3′LTR region — 5′-CTTGTCTTCTTTGGGAGTGAATT AGC-3′, and
the probe 5′-6-carboxylﬂuorsecein-TCCACACTGACTAAAAGGGTCT-
GAGGGATCTCT-carboxytetramethylrhodamine-3′ (IDT) or LTR–Gag
region: 5′LTR region — 5′ CTAGGGAACCCACTG-′3 and Gag — 5′-
CAGACCCTTTTAGTCAGTGTGGAA-3′ and the probe 5′-6-carboxyl-
ﬂuorsecein-TCTCTAGCAGTGGCGCC-carboxytetramethylrhodamine-
3′ (IDT). For the late product PCR, DNase digestions (Turbo DNase,
Ambion) were conducted to correct for vector contamination in late
product Q-PCR. For the PCR background control, the cells were pre-
treated with 2 μM Nevirapine and 1 μM AZT (NIH AIDS reagent
program). Digestions were preformed on vector prior to transduc-
tion and on the transduced cells prior to lyses. The ampliﬁcation and
quantitation were carried out as previously described (Jamburuthu-
hugoda et al., 2006).
dN effect assay and serum starvation
To elevate the dNTP concentration, HLFs were treated with 1)
1.0 mM of all dNs (Sigma) 2 h prior to the transduction of virus or 2)
1.0 mM dC, or 3) 1.0 mM of all dNs without dC (dA, dT, and dG), 2 h
after 3TC treatment, and then 24 h after transduction. To lower thecellular dNTP concentration, cells were cultured in DMEM supple-
mented with 0.2% FBS 48 h prior to and throughout vector
transduction.
Altering the ratio of WT and M184I RT packaged in a virion
To produce vectors with varying concentrations of packaged RT,
293FT cells were transfected with the following amounts of WT (−)
cPPT to M184I (−) cPPT vector DNA: 0:25, 2.5:22.5, 12.5:12.5,
22.5:2.5, and 25 μg: 0 μg. Each transfection included 5 μg of VSV-G
vector DNA.
Generation of IC50 values for 3TC Nevirapine and AZT in HLFs
HLFs cultured in DMEM supplemented with 10% FBS were pre-
treated 2 h before transduction and 24 h after transduction (Moravek
Biochemicals) in the following concentrations (0, 25, 100, 250, 500
and 750 μM/0, 0.25, 0.5, 1, 2, 4, and 6 μM) with 3TC, (0, 2.5, 5, 10, 30,
50, 75, 100, 150, 200 nM/0, 75, 100, 150, 200, 300, and 400 nM) of
Nevirapine, or (0.32, 0.64, 1.28, 4, 8, 16 μM) of AZT (NIH AIDS reagent
program). The HLFs were transduced with equal p24 levels
(2.77×105 pg). HLFs expressing eGFP were quantitated at 48 h post
transduction through FACS. IC50 values were calculated using a best-
ﬁt curve (Prism).
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